✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Cagrilintide Peptide: Long-Acting Amylin Analogue Research Guide

Cagrilintide is the long-acting amylin-receptor agonist developed by Novo Nordisk as the stack partner to semaglutide. While the molecule has documented standalone activity, the primary research interest is the combination — the CagriSema architecture sits as one of the two leading “deeper than GLP-1 monoagonism” approaches in the modern obesity-pharma literature (the other being retatrutide’s triple-agonist single-molecule approach). This guide covers the amylin mechanism, the combination context, and the research applicability.

What is cagrilintide

Cagrilintide is a 37-amino-acid synthetic analogue of amylin (also called islet amyloid polypeptide / IAPP). Native amylin is a pancreatic hormone co-secreted with insulin from beta cells; its natural half-life is short (~13 minutes) due to rapid receptor-mediated clearance. Cagrilintide carries acylation modifications that support albumin binding, extending plasma half-life to ~8 days and enabling weekly subcutaneous dosing. The receptor specificity is preserved — the molecule binds amylin receptors with high affinity and selectivity.

Mechanism

Amylin signalling operates through a different physiological pathway than the GLP-1 / GIP / glucagon family. The amylin receptor is a heterodimeric complex (the calcitonin receptor plus receptor activity-modifying proteins / RAMPs) that is heavily expressed in the area postrema — the brainstem region responsible for meal-termination satiety. Amylin activation produces a satiety signal distinct from GLP-1’s appetite-suppression effect: slower onset, longer duration, and meal-termination-specific rather than general appetite-reducing.

This mechanistic distinctness is the basis for the CagriSema combination logic. GLP-1 acts on hypothalamic and gastric circuits; amylin acts on hindbrain meal-termination circuits. The two pathways don’t substantially overlap in their downstream effects — which means combined activation produces additive weight loss without the side-effect amplification that would occur if both molecules targeted the same circuit.

Research applications

The primary research framing is the CagriSema combination. Phase 2 REDEFINE produced the headline data: cagrilintide 2.4 mg + semaglutide 2.4 mg = -15.7% mean weight loss at 32 weeks, compared with -8.1% for semaglutide alone and -8.0% for cagrilintide alone. The Phase 3 REDEFINE-1 and REDEFINE-2 trials are evaluating the fixed-combination product.

Other research scenarios: standalone amylin-pharmacology mechanism research (using cagrilintide as the reference long-acting amylin analogue); meal-termination-satiety neuroscience research (where the amylin-receptor mechanism is the primary endpoint); comparator research against retatrutide’s triple-agonist single-molecule approach (CagriSema and retatrutide are the two leading non-overlapping-mechanism approaches to deeper-than-monotherapy weight loss).

Research dosing

Phase 3 CagriSema combination uses cagrilintide 2.4 mg weekly SC alongside semaglutide 2.4 mg weekly SC. Standalone cagrilintide research uses similar 2.4 mg weekly doses. Titration is gentler than the GLP-1 class because amylin-receptor side effects are less pronounced — the published Phase 2 protocols escalate from 0.16 mg to 2.4 mg over ~16 weeks but the GI tolerability constraint is substantially less restrictive than for semaglutide or tirzepatide.

Side-effect profile

Substantially gentler than the GLP-1 class. The principal published considerations: bradygastria (slowed gastric emptying, less severe than with GLP-1 agonists), occasional nausea (less prominent than with GLP-1 monotherapy), theoretical effects on bone mineralisation in long-duration animal studies (not confirmed in human-research data), and the general weight-loss-class consideration of gallstone risk with rapid weight loss when used in combination. The CagriSema combination’s overall side-effect profile is closer to semaglutide alone than to a hypothetical “additive of both molecules” pattern — the mechanistic distinctness is the protective factor.

Comparator and stacking

Direct comparator: Cagrilintide vs Semaglutide covers the side-by-side mechanism and trial-data comparison. For the broader incretin-cluster comparison, see the 3-way GLP-1/GIP/glucagon comparison — cagrilintide sits outside this triplet, providing the amylin-arm option distinct from any glucagon-arm or GIP-arm addition. The primary stacking pattern is CagriSema (cagrilintide + semaglutide); other combinations are possible but less-published.

Storage and reconstitution

Lyophilized vials at -20 °C for long-term storage or 2-8 °C as working stock. Reconstitute with bacteriostatic water. Reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.

FAQ

How is amylin different from GLP-1?

Different hormone family, different receptor, different signalling. Amylin is co-secreted with insulin from pancreatic beta cells and acts on hindbrain amylin receptors (calcitonin-receptor heterodimers in the area postrema) to produce meal-termination satiety. GLP-1 is secreted from intestinal L-cells and acts on hypothalamic and vagal-afferent GLP-1 receptors to produce general appetite suppression and slow gastric emptying. The two pathways don’t substantially overlap.

Why is cagrilintide rarely used standalone?

Because the standalone effect size (-8.0% at 32 wk) is comparable to semaglutide standalone but without semaglutide’s deeper effect potential at higher doses. The strategic positioning is as a stack partner: cagrilintide + semaglutide produces additive weight loss without proportional side-effect amplification. Standalone cagrilintide is valid for amylin-mechanism research but doesn’t add weight-loss benefit over semaglutide standalone.

Is CagriSema better than retatrutide?

Direct head-to-head data does not yet exist. Indirect Phase 2 comparison: CagriSema -15.7% at 32 wk vs retatrutide -24.2% at 48 wk. Retatrutide appears deeper at the longer timeframe; matched-window data is pending. The two approaches answer the same question (deeper than GLP-1 mono) via different routes: combination of two molecules vs single triple-agonist molecule.

What’s the typical research dose?

2.4 mg weekly SC, after titration from 0.16 mg over ~16 weeks. In the CagriSema combination, cagrilintide 2.4 mg + semaglutide 2.4 mg, both weekly SC.

Does cagrilintide produce nausea like the GLP-1 class?

Less so. The amylin-receptor mechanism produces a different kind of GI effect (mild bradygastria) rather than the prominent nausea seen with GLP-1 monoagonism. The published Phase 2 data shows CagriSema’s overall GI side-effect rate is closer to semaglutide alone than to a hypothetical additive of both molecules.

Storage protocol?

Lyophilized at -20 °C long-term, 2-8 °C working; reconstituted at 2-8 °C use within 30 days; protect from light; never freeze-thaw.

Bottom line

Cagrilintide is the long-acting amylin analogue developed as the stack partner to semaglutide. The amylin mechanism is non-overlapping with GLP-1 / GIP / glucagon, which is what enables the CagriSema combination’s additive effect without proportional side-effect amplification. For obesity-pharma research, cagrilintide’s primary role is in the CagriSema architecture; for pure mechanism research, it is the reference long-acting amylin compound. The competing approach to deeper-than-monotherapy weight loss is retatrutide’s triple-agonist single-molecule architecture. See Best peptides for fat loss for full cluster context.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.